EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Geroprotective Drug Candidate CMS121 Alleviates Diabetes, Liver Inflammation, and Renal Damage in db/db Leptin Receptor Deficient Mice

Saadia Zahid iD, Alcir L Dafre iD, Antonio Currais iD, Jingting Yu, David Schubert, Pamela Maher iD

International Journal of Molecular Sciences · 06.04.2023 · 24 (7) · 6828

DOI: 10.3390/ijms24076828 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 06.04.2023. Verfasst von Saadia Zahid und 5 weiteren Autor:innen. Beteiligte Einrichtung: Cellular Neurobiology Laboratory, Salk Institute for Biological Studies, La Jolla, CA 92037, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hepatitis. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 108 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

db/db mice, which lack leptin receptors and exhibit hyperphagia, show disturbances in energy metabolism and are a model of obesity and type 2 diabetes. The geroneuroprotector drug candidate CMS121 has been shown to be effective in animal models of Alzheimer’s disease and aging through the modulation of metabolism. Thus, the hypothesis was that CMS121 could protect db/db mice from metabolic defects and thereby reduce liver inflammation and kidney damage. The mice were treated with CMS121 in their diet for 6 months. No changes were observed in food and oxygen consumption, body mass, or locomotor activity compared to control db/db mice, but a 5% reduction in body weight was noted. Improved glucose tolerance and reduced HbA1c and insulin levels were also seen. Blood and liver triglycerides and free fatty acids decreased. Improved metabolism was supported by lower levels of fatty acid metabolites in the urine. Markers of liver inflammation, including NF-κB, IL-18, caspase 3, and C reactive protein, were lowered by the CMS121 treatment. Urine markers of kidney damage were improved, as evidenced by lower urinary levels of NGAL, clusterin, and albumin. Urine metabolomics studies provided further evidence for kidney protection. Mitochondrial protein markers were elevated in db/db mice, but CMS121 restored the renal levels of NDUFB8, UQCRC2, and VDAC. Overall, long-term CMS121 treatment alleviated metabolic imbalances, liver inflammation, and reduced markers of kidney damage. Thus, this study provides promising evidence for the potential therapeutic use of CMS121 in treating metabolic disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2HepatitisMiceAnimalsReceptors, LeptinLiverKidneyMice, Inbred StrainsInflammationMice, Inbred C57BLLeptin

Stichwörter der Autor:innen

Alzheimer’s diseasegeroneuroprotectorinflammationkidney damagemetabolic disordersobesity

Substanzen

Receptors, LeptinLeptin

Autor:innen und Institutionen

  • Cellular Neurobiology Laboratory, Salk Institute for Biological Studies, La Jolla, CA 92037, USA.
  • Neurobiology Research Laboratory, Atta ur Rahman School of Applied Biosciences, National University of Sciences and Technology (NUST), Islamabad 44000, Pakistan.
  • Biochemistry Department, Federal University of Santa Catarina, Florianópolis 88040-900, Brazil.
  • The Razavi Newman Integrative Genomics and Bioinformatics Core, Salk Institute for Biological Studies, La Jolla, CA 92037, USA.

ORCID-Profile: Saadia Zahid, Alcir L Dafre, Antonio Currais, Pamela Maher

Förderung

  • NIA NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Zahid, S., Dafre, A. L., Currais, A., Yu, J., Schubert, D., & Maher, P. (2023). The Geroprotective Drug Candidate CMS121 Alleviates Diabetes, Liver Inflammation, and Renal Damage in db/db Leptin Receptor Deficient Mice. International Journal of Molecular Sciences, 24(7), 6828. https://doi.org/10.3390/ijms24076828

Vancouver

Zahid S, Dafre AL, Currais A, Yu J, Schubert D, Maher P. The Geroprotective Drug Candidate CMS121 Alleviates Diabetes, Liver Inflammation, and Renal Damage in db/db Leptin Receptor Deficient Mice. International Journal of Molecular Sciences. 2023;24(7):6828. doi:10.3390/ijms24076828

BibTeX
@article{Zahid2023,
  author = {Zahid, Saadia and Dafre, Alcir L and Currais, Antonio and Yu, Jingting and Schubert, David and Maher, Pamela},
  title = {The Geroprotective Drug Candidate CMS121 Alleviates Diabetes, Liver Inflammation, and Renal Damage in db/db Leptin Receptor Deficient Mice},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {7},
  pages = {6828},
  doi = {10.3390/ijms24076828}
}
Kostenlos starten →